05/04/2004
ReGen Therapeutics Plc (‘ReGen’), a company developing a potential treatment for Alzheimer’s disease announces that Percy Lomax (Executive Chairman) made a visit to New York on the 22nd to 26th March 2004 to increase recognition of the company and Colostrinin™.
The highlight of the visit was a well-received presentation at the Plaza Hotel to over 50 people from the medical, trade media and financial communities. There were also a series of individual meetings with financial professionals, corporate advisers and corporate entities.
The visit was part of the longer term strategy for ReGen to build a presence in the United States, where it conducts a substantial part of its research and is carrying out its manufacturing scale-up. Therefore, in view of these facts and that the US is by far the largest pharmaceutical market, and the major equity market in the world, securing a presence in the US is a key long term goal for ReGen.
Further information:
Andrew Marshall
Marshall Robinson Roe
Tel No: 020 7960 6007